A new German study found that compared with conventional disease-modifying anti-rheumatic drugs (DMARDs), rates of lower gastrointestinal (GI) perforation, which has a 30 percent mortality rate in the general population, were more than quadrupled with use of tocilizumab (Actemra) in rheumatoid arthritis patients. However, no significant link to GI perforation was seen for the tumor necrosis factor (TNF) inhibitors, abatacept (Orencia), or rituximab (Rituxan).

Click here for more.